PL Developments Forms Nicotine Alternatives Company NicoGen Pharma Solutions, LLC

    WESTBURY, NY, July 27, 2017 /24-7PressRelease/ -- PL Developments (PLD) announced today the formation of a new subsidiary; NicoGen Pharma Solutions, LLC (NicoGen). PLD recognizes the vast opportunity related to the development and introduction of innovative non-combustible nicotine products and smoking cessation aids. As PLD's efforts have intensified, the company has decided to focus its efforts via the creation of NicoGen and has installed Darren Quinn as NicoGen's president.

Quinn brings a wealth of sales, marketing and new product introduction experience in the nicotine industry dating back to 1995. Prior to joining NicoGen Pharma, Quinn served as president of CN Smokeless Company, LLC where he successfully introduced several smokeless tobacco and snus brands. Prior to CNSC, Quinn was CEO at Nordic American Smokeless Inc. (former subsidiary of Taboca A/S), where he spent several years in Scandinavia introducing the iconic brands Montecristo and Romeo y Julieta into the snus category. Quinn's distinguished career began with almost 10 years at UST, Inc. (now a subsidiary of Altria) where increasing responsibilities included international sales and marketing oversight for mega-brands Copenhagen and Skoal moist snuff.

"PLD continues to explore opportunities true to its mission of improving lives through innovation. Nicotine alternative products and smoking cessation aids are in greater demand than ever before and PLD intends to meet this demand through the commercialization of less harmful nicotine alternatives both in the US and abroad," said Evan Singer, president of PLD. "Darren's more than 20 years of experience within the tobacco industry, both domestic and international, makes him a perfect fit to identify strategic partnerships and execute new product introductions," said Singer.

NicoGen's development of orally administered and non-combustible nicotine products are always free from tobacco leaf, tar and any known carcinogens. NicoGen products are formulated with nicotine and other excipients classified as GRAS (Generally Recognized as Safe) by the FDA. Additionally, all products are manufactured in the United States and adhere to cGMP (current good manufacturing practices) in facilities registered and inspected by the FDA.

"PLD's extensive capabilities in product development, cGMP manufacturing, packaging and distribution will set NicoGen's portfolio apart from all other traditional combustible and non-combustible tobacco products," said Quinn. "I look forward to leading the commercialization efforts of an innovative product lineup not seen since the introduction of e-cigarettes," added Quinn.

Nicogen's products are designed to close the gap between traditional tobacco products and NRTs (Nicotine Replacement Therapy). Products will be made available at traditional tobacco channels such as convenience stores and tobacco outlets as well as drug chains and e-commerce sites.

About PL Developments:

Founded in 1988 and headquartered in Westbury, NY. PL Developments is a leading manufacturer, packager and distributor of pharmaceutical and consumer healthcare products. PLD operates pharmaceutical manufacturing facilities across the United States; its operations include more than 1 million square feet of real estate and 1,100 employees. PLD primarily serves US retailers in their store brands with an assortment of more than 450 unique products across several healthcare categories.

About NicoGen Pharma Solutions, LLC: Headquartered in Miami, FL, NicoGen Pharma Solutions, LLC focuses on responsibly developing, manufacturing and marketing alternative nicotine products intended for adult smokers, vapers and dippers. NicoGen's products contain nicotine, purely extracted from the tobacco leaf using steam which is then combined with other GRAS (Generally Recognized as Safe) ingredients. Our nicotine is sourced from the finest tobacco available from around the world and is 100% manufactured in the U.S. in our state-of-the-art, cGMP-certified and FDA-approved facilities.

Media Contacts:
Megan Wilson PL Developments
[email protected]

Melissa Valukis PL Developments
[email protected]

# # #